Nanoparticle Decoys for Organophosphate Toxin Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for organophosphate poisoning, such as organophosphorus compound exposure, are ineffective due to irreversible inhibition of acetylcholinesterase, leading to severe neurotoxic effects and high mortality rates, with existing antidotes causing significant side effects and being difficult to administer effectively.
Innovation Solution
Development of nanoparticles with a non-cellular inner core and a cellular membrane derived from source cells, such as red blood cells, to act as decoys for organophosphate toxins, neutralizing their toxicity by binding to the toxins rather than cellular acetylcholinesterase, thereby preserving enzyme activity and reducing toxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidotes (atropine and oximes) are used to treat organophosphate poisoning, then acetylcholinesterase reactivation is attempted, but serious side effects occur and treatment is difficult to administer effectively
Solution Approach 1:
The patent uses a nanoparticle intermediary with a cellular membrane coating that binds to organophosphate toxins in the bloodstream, preventing them from reaching and inhibiting acetylcholinesterase. This intermediary approach removes the toxin before it can harm the target enzyme, avoiding the side effects associated with traditional antidotes that directly interact with the enzyme or nervous system
Solution Approach 2:
The nanoparticle is coated with a cellular membrane that mimics the structure and properties of natural cell membranes, allowing it to interact with toxins in a physiologically relevant manner. This membrane copy enables the nanoparticle to serve as a safe decoy that binds toxins without triggering the harmful side effects of conventional treatments
2Reliability
If high doses of atropine are administered to achieve sufficient atropinization, then peripheral acetylcholine effects are blocked, but the treatment becomes difficult to administer and side effects increase
Solution Approach 1:
The nanoparticle treatment works by preliminarily binding and removing organophosphate toxins from the bloodstream before they can irreversibly inhibit acetylcholinesterase. This preliminary removal action eliminates the need for high-dose atropine administration and subsequent monitoring to achieve adequate atropinization, simplifying the treatment protocol
3Reliability
If enzyme bioscavengers (human serum BChE and PON1) are used to react and hydrolyze organophosphates, then toxin deactivation occurs, but large-scale production remains a hurdle
Solution Approach 1:
The patent transforms the bioscavenger approach by changing the physical form and delivery parameters. Instead of administering recombinant proteins that require complex large-scale production, the invention uses nanoparticles with cellular membrane coatings that can be produced more readily while achieving the same toxin deactivation function through physical binding rather than enzymatic hydrolysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle-based approach effectively neutralizes organophosphate toxins, significantly increasing survival rates and restoring acetylcholinesterase activity in animal models, offering a safer and more effective treatment option compared to traditional antidotes.
Implementation Method 1
nanoparticle... act as decoys for organophosphate toxins, neutralizing their toxicity by binding to the toxins rather than cellular acetylcholinesterase
Data Source
AI summary
The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.